Enwei Pharmaceutical Co., Ltd. (SZSE:301331) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of its shares. The shares will be repurchased at a price not more than CNY 63.41 per share. The repurchased shares will be used for ESOP or equity incentives. The repurchase period will be not more than 12 months.

On May 23, 2024, the company announced that it has adjusted its repurchase price from CNY 63.41 per share to CNY 42.69 per share.